Signition LP lifted its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 3.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,856 shares of the medical research company’s stock after buying an additional 550 shares during the period. Signition LP’s holdings in PRA Health Sciences were worth $1,572,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its stake in PRA Health Sciences by 1.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 447,357 shares of the medical research company’s stock worth $41,134,000 after purchasing an additional 6,803 shares during the period. Geode Capital Management LLC lifted its stake in PRA Health Sciences by 16.9% during the fourth quarter. Geode Capital Management LLC now owns 641,658 shares of the medical research company’s stock worth $59,006,000 after purchasing an additional 92,838 shares during the period. Nisa Investment Advisors LLC lifted its stake in PRA Health Sciences by 9.4% during the first quarter. Nisa Investment Advisors LLC now owns 8,073 shares of the medical research company’s stock worth $890,000 after purchasing an additional 697 shares during the period. Brinker Capital Inc. lifted its stake in PRA Health Sciences by 17.6% during the first quarter. Brinker Capital Inc. now owns 15,527 shares of the medical research company’s stock worth $1,712,000 after purchasing an additional 2,322 shares during the period. Finally, Creative Planning bought a new position in PRA Health Sciences during the first quarter worth about $512,000. Institutional investors and hedge funds own 95.34% of the company’s stock.
Shares of NASDAQ:PRAH traded down $1.84 during trading on Friday, reaching $95.88. The stock had a trading volume of 163,210 shares, compared to its average volume of 643,211. PRA Health Sciences Inc has a 52 week low of $82.12 and a 52 week high of $121.98. The business’s 50-day moving average price is $98.22 and its 200 day moving average price is $99.73. The company has a debt-to-equity ratio of 1.11, a current ratio of 0.99 and a quick ratio of 0.99. The stock has a market capitalization of $6.44 billion, a PE ratio of 24.40, a P/E/G ratio of 1.31 and a beta of 1.12.
PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, July 31st. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.11. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The company had revenue of $763.31 million during the quarter, compared to analysts’ expectations of $764.95 million. During the same quarter in the previous year, the company posted $1.00 earnings per share. PRA Health Sciences’s quarterly revenue was up 5.6% compared to the same quarter last year. Analysts forecast that PRA Health Sciences Inc will post 4.63 EPS for the current year.
PRAH has been the subject of a number of analyst reports. BidaskClub upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Leerink Swann initiated coverage on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. They set a “market perform” rating and a $105.00 price target for the company. Mizuho set a $100.00 target price on shares of PRA Health Sciences and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Svb Leerink reiterated a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. PRA Health Sciences presently has an average rating of “Hold” and an average target price of $113.40.
PRA Health Sciences Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Story: What is required to own or exchange cryptocurrency?
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.